AR110548A1 - COMPOSITIONS OF AMINO ACIDS AND METHODS FOR THE TREATMENT OF MUSCLE DISEASES AND DISORDERS - Google Patents
COMPOSITIONS OF AMINO ACIDS AND METHODS FOR THE TREATMENT OF MUSCLE DISEASES AND DISORDERSInfo
- Publication number
- AR110548A1 AR110548A1 ARP170103573A ARP170103573A AR110548A1 AR 110548 A1 AR110548 A1 AR 110548A1 AR P170103573 A ARP170103573 A AR P170103573A AR P170103573 A ARP170103573 A AR P170103573A AR 110548 A1 AR110548 A1 AR 110548A1
- Authority
- AR
- Argentina
- Prior art keywords
- entity
- amino acid
- amino acids
- disorders
- compositions
- Prior art date
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicación 1: Una composición que comprende: a) una entidad de (L)-aminoácidos de leucina, una entidad de (R)-aminoácidos de arginina y una entidad de (Q)-aminoácidos de glutamina; b) una entidad de N-acetilcisteína (NAC), por ejemplo, NAC; y c) una entidad de aminoácido esencial (EAA) seleccionada de una entidad de (H)-aminoácido histidina, entidad de (K)-aminoácido lisina, entidad de (F)-aminoácido fenilalanina y entidad de (T)-aminoácido treonina o una combinación de dos, tres o cuatro de los EAAS; siempre que: d) al menos una entidad de aminoácidos no se proporcione como un péptido de más de 20 residuos de aminoácidos de largo; y en donde: (i) la entidad de aminoácidos de (a) se selecciona de la tabla 2; y (ii) una o ambas entidades de R-aminoácidos y entidades de Q-aminoácidos están presentes en una mayor cantidad (% en peso) que la entidad de L-aminoácidos.Claim 1: A composition comprising: a) an entity of (L) -amino acids of leucine, an entity of (R) -amino acids of arginine and an entity of (Q) -amino acids of glutamine; b) an N-acetylcysteine (NAC) entity, for example, NAC; and c) an essential amino acid (EAA) entity selected from a (H) -amino acid histidine entity, (K) -amino acid entity, (F) -amino acid phenylalanine entity and (T) -amino acid threonine entity or a combination of two, three or four of the EAAS; provided that: d) at least one amino acid entity is not provided as a peptide of more than 20 amino acid residues in length; and wherein: (i) the amino acid entity of (a) is selected from table 2; and (ii) one or both R-amino acid entities and Q-amino acid entities are present in a greater amount (% by weight) than the L-amino acid entity.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662436073P | 2016-12-19 | 2016-12-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR110548A1 true AR110548A1 (en) | 2019-04-10 |
Family
ID=65895723
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170103572A AR110396A1 (en) | 2016-12-19 | 2017-12-19 | COMPOSITIONS OF AMINO ACIDS AND METHODS OF TREATMENT OF LIVER DISEASES |
| ARP170103573A AR110548A1 (en) | 2016-12-19 | 2017-12-19 | COMPOSITIONS OF AMINO ACIDS AND METHODS FOR THE TREATMENT OF MUSCLE DISEASES AND DISORDERS |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170103572A AR110396A1 (en) | 2016-12-19 | 2017-12-19 | COMPOSITIONS OF AMINO ACIDS AND METHODS OF TREATMENT OF LIVER DISEASES |
Country Status (1)
| Country | Link |
|---|---|
| AR (2) | AR110396A1 (en) |
-
2017
- 2017-12-19 AR ARP170103572A patent/AR110396A1/en unknown
- 2017-12-19 AR ARP170103573A patent/AR110548A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR110396A1 (en) | 2019-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191136A1 (en) | AMINO ACID COMPOSITIONS AND METHODS OF TREATMENT OF HEPATIC DISEASES | |
| CO2022004513A2 (en) | Inhibitory compounds of prmt5 mta–cooperatives | |
| CO2020009997A2 (en) | Solid compositions comprising a glp-1 agonist, a salt of n- (8- (2-hydroxybenzoyl) amino) caprylic acid and a lubricant | |
| CO2018010748A2 (en) | Antiviral agents against hepatitis b | |
| UY37998A (en) | ANTIVIRAL AGENTS AGAINST HEPATITIS B | |
| CO2020002980A2 (en) | Antiviral agents against hepatitis b. | |
| CO2017008862A2 (en) | Pharmaceutical compositions comprising n- (3,5-dimethoxyphenyl) -n '- (1-methyl ethyl) -n- [3- (1-methyl-1h-pyrazol-4-yl-quinoxalin-6-yl] ethane-1 , 2-diamine | |
| UY33479A (en) | THERAPEUTIC COMPOUNDS, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, TREATMENT METHOD AND ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT | |
| SV2018005621A (en) | INHIBITOR OF MUTED DEHYDROGENASE ISOCITRATE IDH1 R132H | |
| UY37646A (en) | INDOLINA DERIVATIVES REPLACED AS INHIBITORS OF THE DENGUE VIRIC REPLICATION | |
| MX2023009652A (en) | Structure-based peptide inhibitors of alpha-synuclein aggregation. | |
| BR112016021034A8 (en) | pharmaceutical composition, use thereof and kit | |
| CO2020010193A2 (en) | A pharmaceutical composition for anemia | |
| CL2020002797A1 (en) | Solid compositions comprising a glp-1 agonist and a salt of n- (8- (2-hydroxybenzoyl) amino) caprylic acid | |
| BR112021020883A2 (en) | Solid forms of a glyt1 inhibitor | |
| BR112019007543A2 (en) | alpha-amino-beta-carboximuconic acid inhibitors semialdehyde decarboxylase | |
| BR112022007718A2 (en) | PHARMACEUTICAL COMPOSITION, AND, METHODS OF TREATMENT OF A SUBJECT IN NEED AND FOR PRODUCTION OF A SOLID PHARMACEUTICAL COMPOSITION | |
| CL2021000930A1 (en) | Novel Pyridazines | |
| BR112019003816A2 (en) | hair rinse treatment composition, method for treating chemically damaged hair and use of a composition | |
| EA201691792A1 (en) | PHARMACEUTICAL COMPOSITIONS BASED ON VILDAGLIPTINA | |
| CO2022000575A2 (en) | Solid compositions comprising an egf(a) derivative and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid | |
| BR112018015629A2 (en) | "compound, composition, method for treating a mammal infected with hiv virus, and triple mutant protein" | |
| BR102016012501A2 (en) | peptide, pharmaceutical composition, use of the peptide, and, use of the pharmaceutical composition | |
| PE20180691A1 (en) | VARIANTS OF IL-37 | |
| MY189021A (en) | Peptides and uses therefor as antiviral agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |